← Trials/Trial dossier/NCT00408525

CompletedPhase 1

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease

Lead sponsor

Vanderbilt University

Asset

Donepezil

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age 40-85

Primary endpoint

•Changes in brain activation patterns as measured in an fMRI

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID040686

NCT IDNCT00408525

Timeline

Milestones

Study start2006-12 (month precision)

Study first posted2006-12-07estimated

Primary completion2012-08-24actual

Study completion2012-08-24actual

Last update posted2018-02-05actual

Assets

Drug assets

Donepezil

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age40 Years

Maximum age85 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Subjects may report experiencing subjective memory dysfunction, however they must be found by clinical evaluation to have no memory dysfunction

•Neuropsychological test battery in the normal range

•Ages 40-85

Exclusion criteria

•Dementia (Mini-Mental State Exam less than 25/30)

•Left-handedness

•Current medication that could influence cognition

•Medical, psychiatric, and neurologic conditions, including cerebrovascular disease or uncontrolled hypertension

•Claustrophobia

•Surgical clips or implants

•Pacemakers or other implanted electronic devices

•History of sheet metal work

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Neuroimaging

1 endpoint

Primary/protocol endpoint

Changes in brain activation patterns as measured in an fMRI.

Time frame:8 weeks

descriptive

Publications (9)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.